Ulcerative Colitis (UC) Epidemiology Forecast 2025-2034

Ulcerative colitis is a chronic inflammatory condition that affects the colon and rectum to varying degrees. According to estimates, there were 5 million cases of ulcerative colitis worldwide in 2023, and the incidence is rising.

Ulcerative Colitis (UC) Epidemiology Forecast Report Coverage

The “Ulcerative Colitis (UC) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of ulcerative colitis (UC). It projects the future incidence and prevalence rates of ulcerative colitis (UC) across various populations. The study covers age, gender, and type as major determinants of the ulcerative colitis (UC)-affected population. The report highlights patterns in the prevalence of ulcerative colitis (UC) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of ulcerative colitis (UC) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Ulcerative Colitis (UC): Disease Overview

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that mainly affects the colon and rectum. The lining of the digestive tract becomes inflamed and ulcerated with the condition. Constant diarrhea, stomach pain, rectal bleeding, exhaustion, and weight loss are some of the symptoms. The illness may be caused by an overreactive immune response that could be brought on by environmental and genetic factors. The typical course of UC involves flare-ups and remissions, which can negatively affect a person's quality of life and necessitate continuous care.

Ulcerative Colitis (UC): Treatment Overview

Reducing inflammation, controlling symptoms, and avoiding flare-ups are the main goals of treating ulcerative colitis. Common strategies include immune system suppressors, biologics that target inflammatory pathways, and anti-inflammatory medications such as corticosteroids and aminosalicylates. In extreme situations, the colon may need to be removed surgically (colectomy). Long-term disease control also heavily relies on dietary changes, stress reduction, and lifestyle changes.

Epidemiology

The ulcerative colitis epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for ulcerative colitis by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for ulcerative colitis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Diffuse inflammation of the colonic and rectal mucosa is a hallmark of ulcerative colitis (UC), a chronic illness. In 95% of cases, UC affects the rectum. It can spread continuously and circumferentially to more proximal areas of the large intestine.
• According to a meta-analyses of population-based cohort studies, 5 out of 10 studies included information on mortality from UC. According to the authors, 17% of deaths among UC patients were attributable to the disease on average.
• According to population-based studies, 14-35% of patients with ulcerative colitis have extensive pancolitis at presentation, 16-45% have left-sided colitis, and 30-60% have proctitis.
• Some studies addressed that even after five years, 10-19% of patients may experience proximal ulcerative colitis, and by ten years, up to 28% of patients may experience it as well.

Country-wise Ulcerative Colitis (UC) Epidemiology

The Ulcerative Colitis (UC) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of ulcerative colitis (UC) varies between countries owing to differences in factors such as genetic predisposition, western diets high in processed foods, environmental factors, hygiene factors, and gut microbiota changes, among others. According to the US National Health and Nutrition Examination Survey (NHANES) data, it was discovered that 2.39 million Americans, or 0.7% of the total population, suffer from IBD. An estimated 1.253 million of them received an ulcerative colitis diagnosis. The yearly incidence of ulcerative colitis in North America is roughly 15 cases per 100,000 people.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Ulcerative Colitis (UC) based on several factors.
• Ulcerative Colitis (UC) Epidemiology Forecast Report covers data for the 8 major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of Ulcerative Colitis (UC) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of ulcerative colitis (UC) epidemiology in the 8 major markets?
• What will be the total number of patients with ulcerative colitis (UC) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of ulcerative colitis (UC) in the 8 major markets in the historical period?
• Which country will have the highest number of ulcerative colitis (UC) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of ulcerative colitis (UC) during the forecast period of 2025-2034?
• What are the currently available treatments for ulcerative colitis (UC)?
• What are the disease risks, signs, symptoms, and unmet needs of ulcerative colitis (UC)?

This product will be delivered within 3-5 business days.